OBJECTIVE: To determine whether community-acquired MRSA sinusitis can be adequately treated on an outpatient basis without the need for intravenous antibiotics. STUDY DESIGN AND SETTING: Retrospective review of all cases of community-acquired MRSA sinusitis encountered by the author over a 36-month period. RESULTS: Of 29 patients who tested positive for MRSA sinusitis, 26 patients had follow-up information available and were retrospectively reviewed. The average follow-up period was 12.0 months (range: 1-36 mo). Twelve infectious episodes of MRSA were treated with oral antibiotics alone and 16 were treated with a combination of oral and topical antibiotics. The mean time to clinical resolution with these regimens was 5.7 weeks (range: 3-8 wks). Two patients experienced recurrent MRSA infections resulting in a recurrence rate of 7.7% and an overall resolution rate of 92.3%. CONCLUSIONS: Community-acquired MRSA sinusitis can be very adequately treated on an outpatient basis with culture-directed oral and topical antibiotics.
OBJECTIVE: To determine whether community-acquired MRSAsinusitis can be adequately treated on an outpatient basis without the need for intravenous antibiotics. STUDY DESIGN AND SETTING: Retrospective review of all cases of community-acquired MRSAsinusitis encountered by the author over a 36-month period. RESULTS: Of 29 patients who tested positive for MRSAsinusitis, 26 patients had follow-up information available and were retrospectively reviewed. The average follow-up period was 12.0 months (range: 1-36 mo). Twelve infectious episodes of MRSA were treated with oral antibiotics alone and 16 were treated with a combination of oral and topical antibiotics. The mean time to clinical resolution with these regimens was 5.7 weeks (range: 3-8 wks). Two patients experienced recurrent MRSA infections resulting in a recurrence rate of 7.7% and an overall resolution rate of 92.3%. CONCLUSIONS: Community-acquired MRSAsinusitis can be very adequately treated on an outpatient basis with culture-directed oral and topical antibiotics.
Authors: Valin Rujanavej; Ethan Soudry; Niaz Banaei; Ellen Jo Baron; Peter H Hwang; Jayakar V Nayak Journal: Am J Rhinol Allergy Date: 2013 Mar-Apr Impact factor: 2.467